علاج داء كرون النشط من متوسط إلى شديد لدى المرضى الذين لم يتلقوا علاجات متقدمة

References

1. In adult outpatients with moderate-to-severely active CD who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab), rather than a LOWER efficacy medication (certolizumab pegol, upadacitinib).
2. CDAI scores <150 suggest clinical remission, and scores 150–220, 221–450, and >450 denote mild, moderate, and severe disease, respectively.